Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
Que
de nuevo ?
Jhay
Zamorano
Hospital Clnico San Carlos, Madrid
Slide 1
General
population
WOSCOPS,
AF/TexCAPS,
MEGA, JUPITER
At-risk
individuals
and groups
HPS, PROSPER,
ALLHAT-LTT,
ASCOTT, CARDS
CHD and
stroke
patients
ACS
Slide 3
(%)
Eventos Coronarios
4S-P
Y=0.1629x 4.6776
2
R = 0.9029
P< 0.0001
as
m
nto HPS-S
a
Cu
20
15
10
j or
e
m
o
j
ba
LIPID-P
4S-S
CARE-P
LIPID-S
CARE-Rx
PROVE-IT-AT
PROVE-IT-PR
5
0
30
50
70
90
110
130
150
170
190
210
(%)
Eventos Coronarios
Reduccin
Reduccin de
de c-LDL
c-LDL yy reduccin
reduccin
de
de eventos
eventos coronarios
coronarios
Prevencion Secundaria
Prevencion Primaria
25
4S-PL
LIPID-PL
20
4S-Rx
15
CARE-PL
CARE-Rx
10
WOSCOPS-PL
LIPID-Rx
WOSCOPS-Rx
AFCAPS-Rx
AFCAPS-PL
0
50
70
90
110
130
150
170
190
210
Slide 5
30%
riesgo
2.2
30 mg/dL
1.7
1.3
1.0
40
70
100
130
160
190
Estos datos sugieren que por cada aumento de 30 mg/dL en c-LDL, el riesgo
relativo para Enfermedad Coronaria cambia proporcionalmente un 30%
Tomado de Grundy SM, et al. Implications of recent clinical trial for the National Cholesterol Education Program
Adult Treatment Panel III Guidelines. Circulation 2004; 110:227-239.
Slide 6
*1% de
disminucin
en LDL reduce
el riesgo de
Enfermedad
Coronaria un
1%
*Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation,
and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report Scott M. Grundy,.
(Circulation. 2002;106:3143.)
Slide 7
Las Guas
Slide 8
1988 1989
NCEP
ATP II
1990
1991
1992
NCEP
ATP III
Revision
NCEP
ATP III
1996
1997
1998 1999
2000
NICE
1st
ESC Joint
Task Force
2nd
ESC Joint
Task Force
3rd
ESC Joint
Task Force
2006
2007 2008
NICE
Revision
4th
ESC Joint
Task Force
Patients with CHD or CHD risk equivalents conferring a 10-year risk >20%.
Patients with 2 CHD risk factors conferring a 10-year risk of 10%20%.
Adapted from National Cholesterol Education Program Expert Panel. Arch Intern Med. 1988;148:3669; National Cholesterol Education Program
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA. 1993;269(23):30153023; National Cholesterol
Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA. 2001;285(19):24862497;
Grundy SM, et al. Circulation. 2004;110:227239.
Slide 10
Riesgo
moderado alto
equivalentes
2 FR
(riesgo 10-a
>20%)
(riesgo 10-a
10-20%)
Alto riesgo
190 -
: Objetivos LDL-C
Moderado
riesgo
Bajo
riesgo
2 FR
< 2 FR
(riesgo 10-a
<10%)
Target
160
mg/dL
160 -
LDL-C level
Target
130
mg/dL
Target
130
mg/dL
130 -
Target
100
mg/dL
or
optional
100
mg/dL**
100 -
or
optional
70
mg/dL*
70 -
*Therapeutic option in very high-risk patients and in patients with high TG, non-HDL-C<100 mg/dL; ** Therapeutic option; 70
mg/dL =1.8 mmol/L; 100 mg/dL = 2.6 mmol/L; 130 mg/dL = 3.4 mmol/L; 160 mg/dL = 4.1 mmol/L
Riesgo Cardiovascular
(SCORE)
Bajo
Moderado
1
%
Alto
5
%
Factor de
riesgo
individual muy
elevado
Muy Alto
10
%
ECV documentada
DM2
DM1 con dao
rganos
IRC moderada
EHJ 2011;32:1769-1818
Principios fundamentales de la
evaluacin del riesgo cardiovascular
total
______________________________________
Las personas que presentan:
antecedentes de enfermedad cardiovascular clnica, diabetes de
tipo 2 o de tipo 1 con microalbuminuria, niveles muy patolgicos
de algn factor de riesgo concreto o insuficiencia renal crnica
quedan clasificadas de forma automtica como de riesgo
cardiovascular total alto o muy alto y necesitan tratamiento
intensivo de todos los factores de riesgo presentes.
Objetivos teraputicos
cLDL
Pacientes
Objetivo LDL
Clas Nive
e
l
70 mg/dl (<1,8
mmol/l) y/o reduccin
del cLDL 50% cuando
no pueda alcanzarse el
objetivo
100 mg/dl (<2,5
mmol/l)
IIa
Pacientes de riesgo
moderado
IIa
EHJ 2011;32:1769-181
EHJ 2011;32:1769-1818
Hipercolesterolemia
Recomendaciones para el
tratamiento
Recomendacin
Clas Nive
e
l
IIa
IIb
IIb
EHJ 2011;32:1769-1818
Hipertrigliceridemia
Recomendaciones para el
tratamiento
Recomendacin
Clas Nive
e
l
I
IIa
IIa
IIa
IIa
IIa
IIb
B
B
C
B
A
C
B
EHJ 2011;32:1769-1818
Patients
n
Prior Statin Use
CI estable
Todos
4162
4497
10001
8888
27548
25.2%
0%
0%
75.5%
28.2%
160
LDL-C (mg/dL)
140
120
Basal
100
80
60
Standard
Intenso
40
PROVE ITTIMI 22
A-to-Z
TNT
IDEAL
Pooled
Basal*
108.4
112.9
152
121.5
129.6 (3.32)
Standard*
97.1
101
101
104
101.4 (2.6)
Intenso
65.5
69.1
77
81
75.4 (1.93)
Slide 21
Meta-Analisis de To Intensivo
Endpoints
Odds
Reduction
Event Rates
No./Total (%)
High Dose
Std Dose
-16%
3972/13798
(28.8)
4445/13750
(32.3)
Coronary Death or MI
OR, 0.84
95% CI, 0.77-0.91
p=0.00003
-16%
1097/13798
(8.0)
1288/13750
(9.4)
Cardiovascular Death
OR, 0.88
95% CI, 0.78-1.00
p=.054
-12%
462/13798
(3.3)
520/13750
(3.8)
Non-Cardiovascular
Death
OR, 1.03
95% CI, 0.88-1.20
p=0.73
+3%
340/13798
(2.5)
331/13750
(2.4)
Total Mortality
OR, 0.94
95% CI, 0.85-1.04
P=0.20
-6%
808/13798
(5.9)
857/13750
(6.2)
Stroke
OR 0.82
95% CI, 0.71-0.96
p=0.012
-18%
316/13798
(2.3)
381/13750
(2.8)
OR, 0.84
95% CI, 0.80-0.89
0.5
High-dose statin better
P=.0000000000006
2.5
High-dose statin worse
Novedades
Guas Conjuntas
Slide 23
Slide 24
Objetivo LDL
< 70
o reduccin > 50%
ALTO
< 100
MODERADO
< 115
BAJO
Slide 25